Antares Pharma, Inc. (ATRS)

[rph_investor]

It tests safety and efficacy, and optimization of BID vs. TID dosing. If someone has a vested interest, and the FDA finds out, they will make them repeat if they feel there was bias in the results. I'm sure Novartis (Voltaren Gel maker) would report this to them, if they knew. It would be worth around several million to them to delay it another year. If someone had redness, rash, or other side effects, and had a vested interest, and were dishonest, they wouldn't report it. It's just not smart for an investor to get involved and puts the whole thing at risk. I think we can all agree with that.